IMR Press / FBL / Volume 22 / Issue 10 / DOI: 10.2741/4564

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Clinical, functional, behavioural and epigenomic biomarkers of obesity

Show Less
1 Istituto di Bioimmagini e Fisiologia Molecolare del Consiglio Nazionale delle Ricerche, Segrate, Milano, Italy
2 Departmento de Fisiologia de la Nutricion, Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico D.F., Mexico
3 Departement de Medecine, Universite de Fribourg, Fribourg, Suisse, Switzerland
Front. Biosci. (Landmark Ed) 2017, 22(10), 1655–1681;
Published: 1 March 2017

Overweight and obesity are highly prevalent conditions worldwide, linked to an increased risk for death, disability and disease due to metabolic and biochemical abnormalities affecting the biological human system throughout different domains. Biomarkers, defined as indicators of biological processes in health and disease, relevant for body mass excess management have been identified according to different criteria, including anthropometric and molecular indexes, as well as physiological and behavioural aspects. Analysing these different biomarkers, we identified their potential role in diagnosis, prognosis and treatment. Epigenetic biomarkers, cellular mediators of inflammation and factors related to microbiota-host interactions may be considered to have a theranostic value. Though, the molecular processes responsible for the biological phenomenology detected by the other analysed markers, is not clear yet. Nevertheless, these biomarkers possess valuable diagnostic and prognostic power. A new frontier for theranostic biomarkers can be foreseen in the exploitation of parameters defining behaviours and lifestyles linked to the risk of obesity, capable to describe the effects of interventions for obesity prevention and treatment which include also behaviour change strategies.

Clinical biomarkers
Muscle impairment
Sedentary behaviours
Back to top